Characterization of a thrombin cleavage site mutation (Arg 1689 to Cys) in the factor VIII gene of two unrelated patients with cross-reacting material-positive hemophilia A.

The molecular defect responsible for moderate and severe hemophilia A has been identified for two unrelated patients with the CRM-positive form of this disorder (factor VIII activity of 0.02 and 0.05 U/mL with factor VIII antigen of 0.87 and 2.20 U/mL). In both cases, the immunopurified dysfunctional factor VIII protein is abnormal, in that the 80 Kd light chain is not cleaved by thrombin at arginine-1689. The basis for this failure was identified by polymerase chain reaction amplification of exon 14 of the variant factor VIII genes and direct sequencing of the amplified products. In both cases, a single base substitution (C to T) was identified that produces an arginine to cysteine substitution at amino acid residue 1689. These data identify the molecular defects of the two identical factor VIII variant proteins. The dysfunctional factor VIII has been designated "Factor VIII-East Hartford," the residence of the patient in whom the defect was first identified.

[1]  S. Antonarakis,et al.  Direct characterization of factor VIII in plasma: detection of a mutation altering a thrombin cleavage site (arginine-372----histidine). , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[2]  E. Tuddenham,et al.  Purification and characterization of factor VIII 1,689-Cys: a nonfunctional cofactor occurring in a patient with severe hemophilia A. , 1989, Blood.

[3]  B. Levinson,et al.  Mutations of factor VIII cleavage sites in hemophilia A. , 1988, Blood.

[4]  S. Antonarakis,et al.  The molecular basis of hemophilia A in man. , 1988, Trends in genetics : TIG.

[5]  R. Kaufman,et al.  Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[6]  S. Antonarakis,et al.  Haemophilia A resulting from de novo insertion of L1 sequences represents a novel mechanism for mutation in man , 1988, Nature.

[7]  W. Kane,et al.  Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. , 1988, Blood.

[8]  S. Antonarakis,et al.  Characterization of five partial deletions of the factor VIII gene. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Antonarakis,et al.  Recurrent mutations in haemophilia A give evidence for CpG mutation hotspots , 1986, Nature.

[10]  G. Vehar,et al.  Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. , 1986, Biochemistry.

[11]  S. Antonarakis,et al.  Hemophilia A. Detection of molecular defects and of carriers by DNA analysis. , 1985, The New England journal of medicine.

[12]  L. Holland,et al.  Human factor VIII procoagulant protein. Monoclonal antibodies define precursor-product relationships and functional epitopes. , 1985, The Journal of clinical investigation.

[13]  J. Roberts,et al.  Thrombin proteolysis of purified factor viii procoagulant protein: correlation of activation with generation of a specific polypeptide. , 1983, Blood.

[14]  E. Tuddenham,et al.  Immunologic studies of factor VIII coagulant activity (VIII:C) 1. Assays based on a haemophilic and an acquired antibody to VIII:C. , 1981, Thrombosis research.

[15]  J. Lavergne,et al.  Immunoradiometric Assay of Factor VIII: Coagulant Antigen using Four Human Antibodies. Study of 27 Cases of Haemophilia A , 1981, British journal of haematology.

[16]  H. Reisner,et al.  Factor VIII coagulant antigen in hemophilic plasma: a comparison of five alloantibodies. , 1980, Blood.

[17]  L. Hoyer,et al.  Immunoradiometric measurement of the factor VIII procoagulant antigen. , 1978, The Journal of clinical investigation.

[18]  L. Hoyer.  Immunologic studies of antihemophilic factor (AHF, factor VIII). IV. Radioimmunoassay of AHF antigen. , 1972, The Journal of laboratory and clinical medicine.

[19]  L. Hoyer,et al.  Immunologic studies of antihemophilic factor (AHF, factor VIII): cross-reacting material in a genetic variant of hemophilia A. , 1968, Blood.

[20]  Henry A. Erlich,et al.  Characterization of β-thalassaemia mutations using direct genomic sequencing of amplified single copy DNA , 1987, Nature.

[21]  E. Chen,et al.  Detection and sequence of mutations in the factor VIII gene of haemophiliacs          , 1985, Nature.

[22]  L. Hoyer,et al.  The effect of thrombin on human factor VIII. Cleavage of the factor VIII procoagulant protein during activation. , 1981, The Journal of laboratory and clinical medicine.